Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224329 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6935578 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL633588 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6936201 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6150895 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL633484 | 0.90 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6866936 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R | |
| SCHEMBL4648170 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R | |
| SCHEMBL6866940 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R | |
| SCHEMBL5176774 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030027854-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | SHIONOGI & CO., LTD. | 2003-02-06 | — | — | US | disclosed |
| US-6506789-B2 | For prophylaxis and therapy of itching derived from contact dermatitis, allergic conjunctivitis, urticaria, atopic dermatitis | SHIONOGI & CO., LTD. (JP) | 2003-01-14 | — | — | US | disclosed |
| EP-0944614-B1 | BENZOTHIOPHENECARBOXAMIDE DERIVATIVES AND PGD2 ANTAGONISTS COMPRISING THEM | SHIONOGI & CO (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-20020058693-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | ARIMURA AKINORI (JP) | 2002-05-16 | — | — | US | disclosed |
| EP-1084711-A1 | REMEDIES FOR ITCHING CONTAINING PGD 2? ANTAGONISTS | SHIONOGI & CO., LTD. (JP) | 2001-03-21 | — | — | EP | disclosed |
| US-6083974-A | BENZOTHIOPHENECARBOXAMIDE CONTAINING NORPINANE RING IS USEFUL FOR PREVENTING NASAL BLOCKAGE | SHIONOGI & CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058693-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | HRH2, PTGER2, PTGDR2 | PTGDR 4/4885TBXA2R 18/4885 |
| US-20030027854-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | HRH2, PTGER2, PTGDR2 | PTGDR 4/4885TBXA2R 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.